Given that both pathways regulate angiogenesis and vascular normalization, combinatorial targeting of NCL and VEGF-A–VEGFR2 to normalize the brain tumor vasculature may be a promising antiangiogenic strategy for GBM patients. The gene discussed is VEGFA; the disease is brain neoplasm.